Core Laboratories Q1 Earnings Miss Estimates, Expenses Increase YoY

In This Article:

Core Laboratories Inc. CLB reported first-quarter 2025 adjusted earnings of 8 cents per share, which missed the Zacks Consensus Estimate of 15 cents. The bottom line also underperformed the year-ago quarter’s reported figure of 13 cents. This can be attributed to the underperformance of the Reservoir Description segment.

This oil-field service provider reported operating revenues of $124 million, in line with the Zacks Consensus Estimate. However, the top line decreased 4.6% from the year-ago quarter’s $130 million. This can be attributed to the recent imposition of sanctions and operational inefficiencies.

 

Core Laboratories Inc. Price, Consensus and EPS Surprise

Core Laboratories Inc. Price, Consensus and EPS Surprise
Core Laboratories Inc. Price, Consensus and EPS Surprise

Core Laboratories Inc. price-consensus-eps-surprise-chart | Core Laboratories Inc. Quote

During the first quarter, the company repurchased 131,598 shares of common stock for a total of $2 million. Additionally, CLB continues to maintain its debt leverage ratio at 1.31 and decreased its net debt by $4.9 million.

During the first quarter of 2025, the company's leverage ratio (calculated as total net debt divided by trailing twelve months adjusted EBITDA) remained at the lowest level in eight years.

Segmental Performance of Core Laboratories

Reservoir Description: Revenues in this segment decreased about 4% to $80.9 million from $84.2 million in the first quarter of 2024. However, the top line missed our estimation of $83 million.

Operating income decreased from $11.43 million in the year-ago period to $7.76 million and missed our estimate of $9.64 million. This was due to a combination of multiple factors like a continued seasonal pattern, geopolitical conflicts and recently imposed sanctions and tariffs.

Production Enhancement: This segment’s revenues decreased 6% to $42.7 million from $45.4 million in the prior-year quarter. However, the top line beat our estimate of $41.21 million.

Operating income increased marginally from $3.41 million in the year-ago period to $3.44 million and also beat our estimate of $1.66 million. This was backed by increased demand for diagnostic services in the United States, both onshore and offshore and improved U.S. product sales.

Costs & Expenses of CLB

CLB reported total costs and expenses of $119.2 million in the first quarter, increasing 1.6% from the year-ago quarter’s level. The figure was also higher than our estimation of $113.2 million.

(Find the latest earnings estimates and surprises on Zacks Earnings Calendar.)

CLB’s Financials & Dividends

As of March 31, 2025, the company had cash and cash equivalents of $22.1 million and long-term debt of $124.4 million. CLB’s debt-to-capitalization was 32.4%.